

AMENDMENTS TO THE SPECIFICATION

Please amend the first paragraph on page 1 as follows:

CROSS-REFERENCE TO RELATED APPLICATION

~~This national phase application is a continuation application of International Application No. PCT/EP2004/00109, filed January 9, 2004, which claims benefit of International Application No. PCT/EP2003/07551, filed July 11, 2003. This national phase application also claims benefit of U.S. Application No. 10/520,931, filed January 12, 2005, which is a national phase application of International Application No. PCT/EP2003/07551, filed July 11, 2003, which claims priority to German Patent Application No. 102 31655.4, filed July 12, 2002. This application is a continuation-in-part of U.S. Application No. 10/520,931, filed on December 12, 2005, currently pending, which is a National Stage entry under 35 U.S.C. 371 of International Application No. PCT/EP2003/07551, filed July 11, 2003, which claims the benefit of German Patent Appl. No. 102 31 655.4, filed July 12, 2002. This application is also a National Stage entry under 35 U.S.C. 371 of International Application No. PCT/EP2004/00109, filed January 9, 2004, which claims the benefit of International Application No. PCT/EP2003/07551, filed July 11, 2003, which claims the benefit of German Patent Appl. No. 102 31 655.4, filed July 12, 2002.~~ The disclosures of these applications are hereby incorporated by reference in their entireties.

Please amend the first full paragraph on page 13 as follows:

As described in PCT/EP03/075551, the antibody was prepared by immunising mice with TAIC (corresponding to STIC) derived from human monocytes using methods known to the person skilled in the art (Davis, W. C. "Methods in Molecular Biology : Monoclonal Antibody Protocols", New York: Humana Press Inc. Totowa, 1995). A hybridoma cell line was then produced by fusion of a B cell generating the antibody and a myeloma cell from the mouse. Methods used for the preparation of such cell lines are known in the state of the art (Davis, W. C. "Methods in Molecular Biology: Monoclonal Antibody Protocols", New York: Humana Press

Inc. Totowa, 1995 Kohlerr G. Milstein, C."Continuous cultures of fused cells secreting antibody of predefined specificity". Nature 256, 495-497 (1975)). The hybridoma cell line producing the antibody GM-7 was deposited on May 13, 2002 according to the rules of the Budapest Convention at DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkultur GmbH, Mascheroder Weg 1b, D-38124, Braunschweig, Germany) under the accession no. DSM ACC2542.